Published date: 10 November 2022
Last edited date: 2 December 2022
Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.
Contract summary
Industry
Pharmaceutical products - 33600000
Location of contract
WA7 2ES
Value of contract
£359,779,000
Procurement reference
CF-1160900D0O000000rwimUAA
Published date
10 November 2022
Closing date
12 December 2022
Closing time
1pm
Contract start date
1 May 2023
Contract end date
30 April 2025
Contract type
Supply contract
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals
Offer reference number: CM/PHR/22/5675
CM/PHR/22/5675/01 - NHS Framework Agreement for Branded Medicines - National Category Tender Lot 1. Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
CM/PHR/22/5675/02 - NHS Framework Agreement for Branded Medicines - National Tender Lot 2. Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
More information
Previous notice about this procurement
NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals - 1 May 2023
- Opportunity
- Published 10 November 2022
Attachments
-
- Document No. 01 - Invitation to offer covering letter CM_PHR_22_5675.docx
- Document No. 01 - Invitation to offer covering letter CM_PHR_22_5675
-
- Document No. 02 - Terms of offer.doc
- Document No. 02 - Terms of offer
-
- Document No. 04b - Assessment Criteria, Stability Protocol and Additional Specification Requirements.pdf
- Document No. 04b - Assessment Criteria, Stability Protocol and Additional Specification Requirements
-
- Document No. 05 - Selectt offer schedule instructions.docx
- Document No. 05 - Selectt offer schedule instructions
-
- Document No. 05a (i) Selectt Offer schedule - CM_PHR_22_5675_01.xml
- Document No. 05a (i) Selectt Offer schedule - CM_PHR_22_5675_01
-
- Document No. 03 - Framework Agreement and Terms and Conditions.docx
- Document No. 03 - Framework Agreement and Terms and Conditions
-
- Document No. 04a - Quality Assurance Process.pdf
- Document No. 04a - Quality Assurance Process
-
- Document No. 05a (ii) Selectt Offer schedule - CM_PHR_22_5675_02.xml
- Document No. 05a (ii) Selectt Offer schedule - CM_PHR_22_5675_02
-
- Document No. 05b (i) Tender Product listing and usage - CM_PHR_22_5675_01.xlsx
- Document No. 05b (i) Tender Product listing and usage - CM_PHR_22_5675_01
-
- Document No. 05b (ii) Tender Product listing and usage - CM_PHR_22_5675_02.xlsx
- Document No. 05b (ii) Tender Product listing and usage - CM_PHR_22_5675_02
-
- Document No. 05c - Volume discounts or Additional Products Offer Schedule.xlsx
- Document No. 05c - Volume discounts or Additional Products Offer Schedule
-
- Document No. 06 - Form of offer.doc
- Document No. 06 - Form of offer
-
- Document No. 07a - Quality control technical sheet.pdf
- Document No. 07a - Quality control technical sheet
-
- Document No. 07b - Quality Assurance Policy to support the National Contract Procurement of Licensed Medicines - Edition 5.1 September 2022.pdf
- Document No. 07b - Quality Assurance Policy to support the National Contract Procurement of Licensed Medicines - Edition 5.1 September 2022
-
- Document No. 08 - Confidential information schedule.xls
- Document No. 08 - Confidential information schedule
-
- Document No. 09 - Tender design and instructions on completing the offer schedule.doc
- Document No. 09 - Tender design and instructions on completing the offer schedule
-
- Document No. 10 - Participating authorities.xlsx
- Document No. 10 - Participating authorities
-
- Document No. 00 - Read Me First Document 5675.docx
- Document No. 00 - Read Me First Document 5675
-
- Document No. 05d - Supplementary usage data for Buprenorphine Methylphenidate and Oxycodone.xlsx
- Document No. 05d - Supplementary usage data for Buprenorphine Methylphenidate and Oxycodone
About the buyer
Contact name
Katie Noonan
Address
2nd Floor Rutland House
Runcorn
WA7 2ES
GB
Share this notice
Closing: 12 December 2022, 1pm